Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gabor Hollo et al. – The brinzolamide/timolol fixed combination can be used by itself as a separate therapy, but owing to the additivity of its ingredients to IOP–lowering drugs belonging to other classes, it may also be administered adjunctive to other IOP–reducing molecules, most importantly topical prostaglandin analogues. The ocular and systemic tolerance of the brinzolamide/ timolol fixed combination was reported favorable in Phase III studies, but no long–term clinical experience with this preparation is available at present.

Related Articles

Glaucoma and dry eye data from Germany
Ophthalmology Times Europe, 10/27/09    Relevance Score: 93%

Understanding the Importance of IOP Variables in Glaucoma
Survey of Ophthalmology, 10/23/09    Relevance Score: 92%

Characteristics of respondents with glaucoma and dry eye in a national panel survey
Clinical Ophthalmology, 11/13/09    Relevance Score: 91%

Gene-directed therapy in glaucoma may have future clinical applications
Ophthalmology Times Europe, 10/22/09    Relevance Score: 91%

Sequential Glaucoma Implants in Refractory Glaucoma
American Journal of Ophthalmology, 10/20/09    Relevance Score: 91%

Today in Clinical Pharmacology...keeping you current

Pharmacological and environmental factors in primary angle-closure glaucoma
British Medical Bulletin, 11/25/09

Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated With Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%
Retina, 11/25/09

Infliximab and anterior optic neuropathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 11/23/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address